PARADIGM BIOPHARMACEUTICALS LIMITED.. (PAR)

Shareholders in this company should consider crystallising a capital loss in 2026/27 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.

The company securities are suspended from quotation due to insufficient financial condition following the appointment of voluntary administrators. This suspension, in line with Listing Rules 17.3 and 12.2, will persist until ASX confirms PAR's compliance with listing requirements for reinstatement.

Christopher Pattinson and Hayden White of FTI Consulting are appointed as Joint and Several Administrators

The company requests the continuation of its voluntary suspension from trading on ASX codes PAR and PAROB, starting 28 September 2026. This suspension is necessary for reviewing interim analysis data from its Phase 3 clinical trial and assessing operational and financial implications. The Company seeks to prevent an uninformed market and intends to update by 30 September 2026, with no known reasons against the suspension.

The company lodges its notice of cessation of securities.

The company has agreed to return US$2 million to Obsidian Global GP, LLC and cancel 2,000,000 Convertible Notes linked to the drawdown announced on 11 September 2026. This decision comes as Paradigm evaluates interim analysis findings from its Phase 3 clinical trial for knee osteoarthritis, affecting cash reserves and future funding needs.

The interim efficacy results for PARA_OA_012 fell below the required continuation threshold, leading to trial cessation due to pre-specified futility criteria. Operational challenges caused significant missing data, impacting these results. Paradigm Biopharmaceuticals is reviewing data to understand the implications and has requested a voluntary suspension of its securities under ASX Listing Rule 17.2 until an announcement regarding financial and funding implications is made by 28 September 2026. The Board expresses disappointment and will provide updates as information becomes available.

Paradigm Biopharmaceuticals Limited securities are suspended from quotation under Listing Rule 17.2 at PAR's request, pending an announcement. Suspension lasts until PAR's requested period ends or the announcement is released, unless ASX decides differently.

The suspension of trading in the options of Paradigm Biopharmaceuticals Limited will be lifted immediately.

The options of Paradigm Biopharmaceuticals Limited will be suspended immediately in accordance with Listing Rule 17.3, as there will be no deferred settlement trading. The options are expected to be quoted on a normal settlement basis on Tuesday, 28 November 2023. The suspension only applies to PAR's options and does not apply to any other quoted securities of PAR.

The suspension of trading in the securities of Paradigm Biopharmaceutics Limited will be lifted immediately, following the release by PAR of an announcement regarding the completion of a capital raising.

Bids received significantly exceeded the size of the placement. PAR fully funded to Phase 3 OA trial completion and readout. Support from large Australian and International institutional investors. Significant endorsement of PAR and its treatment of OA. Capital raising enables PAR to be focused on the clear path to regulatory approval and commercialisation.

The company releases a notice of Proposed issue of Securities - PAR.

The company will host a conference call at 8:30am (AEST) Wednesday 8th April to discuss the recent minutes provided by the US FDA and guidance over the requirements for the Phase 3 clinical trial design and NDA submission. The company will also discuss the recent SAS data on 34 patients who have been treated using the Phase 3 material and measured with the same endpoints that will be used in the Phase 3 clinical trials. Investors are encouraged to send through questions by 8:00pm (AEST) Tuesday 7th April, with the company collating questions sent and will endeavour to answer the most frequently asked. Questions are to be submitted to investorrelations@paradigmbiopharma.com.

Paradigm reports very encouraging real-world data ahead of its phase 3 OA clinical trial using the Phase 3 product and two Phase 3 endpoints.

The company receives clarity on US regulatory pathway. The pre-IND meeting was both positive and informative for Paradigm. The positive outcomes from the meeting were clear guidance around the primary and secondary endpoints for the Phase 3 clinical trial, the number of Phase 3 studies required for registration and overall clarity and guidance over the requirements for the Phase 3 clinical trial design and NDA submission.

The company releases its latest Corporate Presentation.

The securities of Paradigm Biopharmaceuticals Limited will be suspended from quotation immediately under Listing Rules 17.2, at the request of PAR, pending the release of an announcement regarding the proposed capital raising.

listed entity carried for record purposes only